Skip to content
value.today
PolyPid Ltd. logo

PolyPid Ltd.

PYPD
$103 Mmarket cap on Aug 1, 2026+759.8% since Jan 2024
Compare
World rank
#18,597
Revenue
—
For year ending December-2025
Net income
$-34 M
SEC filing
Employees
59
As of December 31, 2025
SEC filing

PolyPid Ltd. in brief

PolyPid Ltd. is a listed company in the Biotechnology industry, based in Israel. Its market value was $103 M on 1 August 2026, which makes it the 18,597th largest listed company in the world and the 199th largest in Israel on this site. It employs about 59 people and Dikla Czaczkes Akselbrad is its chief executive. Its shares trade under the symbol PYPD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About PolyPid Ltd.

PolyPid, BonyPid, Bacfenssi, Baczenssi, Opzifend, Ssisurg, Elyfssi and Bacyssio are our proprietary trademarks. These trademarks are important to our business. Although we have omitted the “®” and “TM” trademark designations for such marks in this annual report on Form 20-F, all rights to such trademarks and service marks are nevertheless reserved.

The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together with the risk factors set forth in Item 3D. of this annual report on Form 20-F and the other reports and documents filed by us with U.S. Securities and Exchange Commission, or the SEC.

From the company's annual report filed with the US SEC: read the report

PolyPid Ltd. timeline

2 events, 2014–2020
  1. 2014
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2020
  4. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of PolyPid Ltd. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$50 M$99 M$149 M$199 M202120222023202420252026

World rank over time

▼ down 1,433 places since 2021
2021-01-01: #15856#15,85620212022-01-07: #21705#21,70520222022-12-25: #30560#30,56020222023-07-30: #31008#31,00820232024-01-05: #30698#30,69820242026-03-08: #10289#10,28920262026-08-01: #17289#17,2892026

Rank in Israel: #172 (Jan 2021) · #280 (Jan 2022) · #398 (Dec 2022) · #440 (Jul 2023) · #436 (Jan 2024) · #35 (Mar 2026) · #200 (Aug 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
9.4×
Free cash flow yield
-27.2%
Net margin
—
Operating margin
—
Return on equity
-311.5%
Liabilities / assets
50.8%
Net debt
$-15M
Profit per employee
$-579 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $6M—FY18Fiscal year ending Dec 2019: revenue —, net income $-7M—FY19Fiscal year ending Dec 2020: revenue —, net income $-37M—FY20Fiscal year ending Dec 2021: revenue —, net income $-43M—FY21Fiscal year ending Dec 2022: revenue —, net income $-40M—FY22Fiscal year ending Dec 2023: revenue —, net income $-24M—FY23Fiscal year ending Dec 2024: revenue —, net income $-29M—FY24Fiscal year ending Dec 2025: revenue —, net income $-34M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-33M$-34M—
Dec 2024——$-28M$-29M—
Dec 2023——$-23M$-24M—
Dec 2022——$-39M$-40M—
Dec 2021——$-43M$-43M—
Dec 2020——$-26M$-37M—
Dec 2019——$-19M$-7M—
Dec 2018——$-18M$6M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-28M$0M$-28M$2.09—
Dec 2024$-22M$0M$-22M$4.91—
Dec 2023$-17M$0M$-17M$16.93—
Dec 2022$-34M$2M$-36M$61.09—
Dec 2021$-32M$3M$-35M$68.27—
Dec 2020$-22M$1M$-22M$4.48—
Dec 2019$-17M$1M$-18M$23.69—
Dec 2018$-17M$3M$-20M$0.86—

SEC filings

Official filings of PolyPid Ltd. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-33 M
Net income
$-34 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$22 M
Total liabilities
$11 M
Total equity
$11 M

As of December-2025

Top 25 institutional investors in PolyPid Ltd.#

As of Sep 30, 2026
25 institutions held 2.6 M shares (about 10.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 10.2%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in PolyPid Ltd.
#InstitutionShares heldChange (shares)% heldValueFiled
1AIGH Capital Management LLC1,246,741-258,000 (-17.15%)5.18%$7 MNov 2, 2026
2DAFNA Capital Management LLC207,9000 (0.00%)0.86%$1 MNov 16, 2026
3Marshall Wace, LLP199,745+84,731 (+73.67%)0.83%$1 MNov 13, 2026
4Rosalind Advisors, Inc.177,011-212,444 (-54.55%)0.74%$1 MNov 16, 2026
5Two Sigma Investments, LP145,022New0.60%$1 MNov 16, 2026
6Renaissance Technologies LLC131,800+15,181 (+13.02%)0.55%$1 MNov 12, 2026
7ADAR1 Capital Management, LLC103,9500 (0.00%)0.43%$1 MNov 16, 2026
8Jane Street Group, LLC98,221+15,095 (+18.16%)0.41%$1 MNov 12, 2026
9Susquehanna International Group, LLP80,454+40,427 (+101.00%)0.33%$0 MNov 16, 2026
10Citadel Advisors LLC53,781+11,499 (+27.20%)0.22%$0 MNov 16, 2026
11Lumbard & Kellner, LLC38,2000 (0.00%)0.16%$0 MNov 12, 2026
12HRT Financial LP24,960-12,344 (-33.09%)0.10%$0 MNov 13, 2026
13B. Riley Wealth Advisors, Inc.20,085+4,955 (+32.75%)0.08%$0 MOct 13, 2026
14HighTower Advisors, LLC13,000+2,000 (+18.18%)0.05%$0 MNov 10, 2026
15Simplex Trading, LLC8,118+7,655 (+1653.35%)0.03%$0 MNov 4, 2026
16Steward Partners Investment Advisory, LLC7,3460 (0.00%)0.03%$0 MNov 13, 2026
17Northwestern Mutual Wealth Management Co3,9680 (0.00%)0.02%$0 MNov 13, 2026
18Osaic Holdings, Inc.4670 (0.00%)0.00%$0 MNov 12, 2026
19Jpmorgan Chase & Co345+297 (+618.75%)0.00%$0 MNov 12, 2026
20Morgan Stanley259-122,877 (-99.79%)0.00%$0 MNov 13, 2026
21Group One Trading LLC200-130 (-39.39%)0.00%$0 MNov 10, 2026
22Assetmark, Inc42New0.00%$0 MOct 21, 2026
23Rockefeller Capital Management L.P.330 (0.00%)0.00%$0 MNov 13, 2026
24Caitong International Asset Management Co., Ltd6-59 (-90.77%)0.00%$0 MOct 29, 2026
25SBI Securities Co., Ltd.10 (0.00%)0.00%$0 MOct 22, 2026

Markets and events: PolyPid Ltd.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
447,180
2.5% of shares · 3.48 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2024-12-24 14:33 UTC, code LUDP, resumed 14:43 UTC

Fails to deliver

  • : 1,037 shares at $4.88
  • : 1,998 shares at $4.83
  • : 1,910 shares at $5.02
  • : 503 shares at $4.90
  • : 1,675 shares at $5.13

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

PolyPid Ltd. scorecard#

Passes 2 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year2.09 vs 4.91Diluted EPS 2.09 in fiscal 2025 against 4.91 the year before (report's currency).
    • ✓Net income higher than five years earlier-$34 M-$34 M in fiscal 2025 against -$37 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$34 MNet income -$34 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-366.4%-366.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.0×Current ratio 1.97 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year176.5%Diluted shares up 176.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

PolyPid Ltd.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

PolyPid Ltd.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Research and development2423162831171413
General and administrative7.24.35.58.09.67.73.65.3
Operating income−33−28−23−39−43−26−19−18
Interest and finance income0.50.40.50.30.50.50.10.1
Other non-operating income (expense)−0.7−1.0−0.9−0.50.5−111224
Income before tax−34−29−24−39−43———
Income tax0.00.00.10.1————
Net income including minority interests———−40−43−37r−6.9r−5.9
Net income attributable to shareholders−34−29−24−40−43−37−6.95.9
Earnings per share, basic2.094.9116.9961.09r68.27r4.4823.69-0.16
Earnings per share, diluted2.094.9116.9361.09r68.27r4.4823.690.86
Shares, weighted average (basic)165.91.40.6r0.6r9.60.60.6
Shares, weighted average (diluted)165.91.40.6r0.6r9.60.60.6
Balance sheet
Cash and cash equivalents6.4165.38.69.84.33.97.8
Other current assets0.00.3r0.51.1————
Current assets15176.114354727—
Property, plant and equipment5.16.17.69.28.85.96.1—
Right-of-use (leased) assets1.72.31.62.4————
Long-term investments——9.3129.4296.4—
Non-current assets7.18.69.3—————
Total assets22251526447634—
Accounts payable2.92.40.81.14.11.01.6—
Debt due within a year1.06.84.01.2————
Current liabilities7.7137.38.68.12.92.6—
Long-term debt—0.66.47.6————
Lease liabilities (non-current)0.61.30.91.2————
Non-current liabilities3.64.91012————
Retained earnings−302−267−238−214−175−132−93—
Shareholders' equity117.7−2.15.83673−88−82
Total liabilities and equity22251526447634—
Shares outstanding18101.70.7r19180.6—
Cash-flow statement
Share-based compensation4.92.83.44.34.84.61.01.0
Cash from operating activities−28−22−17−34−32−22−17−17
Capital expenditure−0.2−0.1−0.2−1.8−2.7−0.8−0.9−3.1
Cash from investing activities−6.7−0.33.81737−41−2411
Debt issued———12————
Debt repaid−6.4−3.3−2.6−0.4————
Shares issued0.5—8.74.4————
Cash from financing activities253210.0161.063389.4
Change in cash−9.210−3.5—————
Report20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of PolyPid Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$27 MPrivate placement after listing$10 to $50 million20equity, optionsSEC
Dec 2024$15 MPrivate placement after listing$10 to $50 million12equity, optionsSEC
Aug 2024$14 MPrivate placement after listing$10 to $50 million17equity, optionsSEC
Jan 2024$35 MPrivate placement after listing$10 to $50 million20equity, optionsSEC
Jun 2019$27 MNo. 2$10 to $50 million361equity, optionsSEC
Feb 2016$8 MNo. 1$2 to $10 million8equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How PolyPid Ltd. compares in Biotechnology

  • Market cap$103 M · higher than 36% of 726
  • Price / book9.4× · lower than 16% of 534
  • FCF yield-27.2% · higher than 36% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
PolyPid Ltd.🇮🇱$103 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at PolyPid Ltd.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show PolyPid Ltd.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about PolyPid Ltd.? Suggest a correction